Brief: Olema Oncology Reports Third Quarter 2022 Financial Results
Nov 8 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS AND
PROVIDES CORPORATE UPDATE
* CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES POSITION
OF
$222.6 MILLION AS OF SEPTEMBER 30, 2022
* QTRLY LOSS PER SHARE $0.57
* Q3 EARNINGS PER SHARE VIEW $-0.77 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX9b3KXD
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs